arrow
M

Marisa Avvedimento

Laval University
H指数:18
被引数:1,392

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Pharmacodynamic effects of cangrelor in patients with or without STEMI undergoing percutaneous coronary intervention: insights from the POMPEII study

替格瑞洛在行经皮冠状动脉介入治疗的ST段抬高型心肌梗死或非ST段抬高型心肌梗死患者中的药效学效应:POMPEII研究的启示

2026-04-150
OAAI
Clinical Impact of In-Hospital Hemoglobin Decline Without Overt Bleeding After Transcatheter Aortic Valve Replacement

经导管主动脉瓣置换术后院内血红蛋白下降而无显性出血的临床影响

2025-11-240
PRE
Sex differences among elderly ACS patients undergoing percutaneous coronary intervention receiving Ticagrelor 60 mg vs. 90 mg

老年ACS患者接受经皮冠状动脉介入治疗时,Ticagrelor 60 mg与90 mg的性别差异

2025-11-010
OA
Association between lipoprotein(a), oxidized phospholipids, and bioprosthetic valve dysfunction following transcatheter aortic valve implantation

脂蛋白(a)、氧化磷脂与经导管主动脉瓣植入术后生物瓣功能障碍之间的关联

2025-11-010
OAAI
P282 ASSOCIATION BETWEEN LIPOPROTEIN(A), OXIDIZED PHOSPHOLIPIDS AND BIOPROSTHETIC VALVE DYSFUNCTION FOLLOWING TRANSCATHETER AORTIC VALVE IMPLANTATION

P282 脂蛋白(A)、氧化磷脂与经导管主动脉瓣植入术后生物瓣功能障碍之间的关联

2025-10-010
PRE
Personalized or Standard Duration of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention: PARTHENOPE Randomized Trial

经皮冠状动脉介入治疗后个体化或标准双重抗血小板治疗持续时间:PARTHENOPE随机试验

JACC
IF0
2025-08-300
PRE
Early Hemodynamic Performance of the SAPIEN 3 Ultra Resilia and Evolut Valves: A Propensity-Matched Analysis.

SAPIEN 3 Ultra Resilia和Evolut瓣膜的早期血流动力学性能:一项倾向性匹配分析。

2025-08-120
PRE
Vascular Complications in Patients Undergoing Transcatheter Aortic Valve Replacement With Contemporary Devices

经导管主动脉瓣置换术患者中当代器械相关的血管并发症

2025-04-090
PRE